Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page or call 1-877-436-3683.

Zora Modrusan - Associate Director, Next Generation Sequencing

Zora Modrusan

Associate Director, Next Generation Sequencing

Years at Genentech

My position at Genentech provides a great opportunity to collaborate with research groups engaged in the validation and development of new therapeutic targets. Working with diverse groups of scientists and having access to cutting edge technology are the key elements that make my job gratifying.

Featured Publication

Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.

Nature Genetics 2015 Jan;47(1):13-21.

Durinck S, Stawiski EW, Pavía-Jiménez A, Modrusan Z, Kapur P, Jaiswal BS, Zhang N, Toffessi-Tcheuyap V, Nguyen TT, Pahuja KB, Chen YJ, Saleem S, Chaudhuri S, Heldens S, Jackson M, Peña-Llopis S, Guillory J, Toy K, Ha C, Harris CJ, Holloman E, Hill HM, Stinson J, Rivers CS, Janakiraman V, Wang W, Kinch LN, Grishin NV, Haverty PM, Chow B, Gehring JS, Reeder J, Pau G, Wu TD, Margulis V, Lotan Y, Sagalowsky A, Pedrosa I, de Sauvage FJ, Brugarolas J, Seshagiri S.